Morrisroe, Kathleen, Nakayama, Ayano, Soon, Jason, Arnold, Mark, Barnsley, Les, Barrett, Claire, Brooks, Peter M., Hall, Stephen, Hanrahan, Patrick, Hissaria, Pravin, Jones, Graeme, Katikireddi, Veera S., Keen, Helen, Laurent, Rodger, Nikpour, Mandana, Poulsen, Katherine, Robinson, Philip, Soden, Muriel, Wood, Nigel, Cook, Nicola, Hill, Catherine, and Buchbinder, Rachelle (2018) EVOLVE: The Australian Rheumatology Association's 'top five' list of investigations and interventions doctors and patients should question. Internal Medicine Journal, 48 (2). pp. 135-143.

PDF (Published Version) - Published Version Restricted to Repository staff only

11

Abstract

Background: The EVOLVE (evaluating evidence, enhancing efficiencies) initiative aims to drive safer, higher-quality patient care through identifying and reducing low-value practices.

Aims: To determine the Australian Rheumatology Association's (ARA) top five' list of low-value practices.

Methods: A working group comprising 19 rheumatologists and three trainees compiled a preliminary list. Items were retained if there was strong evidence of low value and there was high or increasing clinical use and/or increasing cost. All ARA members (356 rheumatologists and 72 trainees) were invited to indicate their top five' list from a list of 12-items through SurveyMonkey in December 2015 (reminder February 2016).

Results: A total of 179 rheumatologists (50.3%) and 19 trainees (26.4%) responded. The top five list (percentage of rheumatologists, including item in their top five list) was: Do not perform arthroscopy with lavage and/or debridement for symptomatic osteoarthritis of the knee nor partial meniscectomy for a degenerate meniscal tear (73.2%); Do not order anti-nuclear antibody (ANA) testing without symptoms and/or signs suggestive of a systemic rheumatic disease (56.4%); Do not undertake imaging for low back pain for patients without indications of an underlying serious condition (50.8%); Do not use ultrasound guidance to perform injections into the subacromial space as it provides no additional benefit in comparison to landmark-guided injection (50.3%) and Do not order anti-double-stranded DNA antibodies in ANA negative patients unless the clinical suspicion of systemic lupus erythematosus remains high (45.3%).

Conclusions: This list is intended to increase awareness among rheumatologists, other clinicians and patients about commonly used low-value practices that should be questioned.

Actions (Repository Staff Only)

Item Control Page